Focal hypoechoic tumors of fatty liver: Characterization of conventional and contrast-enhanced ultrasonography

Journal of Ultrasound in Medicine

Volumn 28, Issue 9, 2009, Pages 1133-1142

  Liu, Li Ping ^a   Dong, Bao Wei ^b   Yu, Xiao Ling ^b   Liang, Ping ^b   Zhang, Da Kun ^b   An, Li Chun ^b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Contrast agent; Fatty liver; Hypoechoic liver tumor; Ultrasonography

Indexed keywords

DISEASES; PATHOLOGY; SULFUR HEXAFLUORIDE; ULTRASONOGRAPHY; WHEELS;

CONTRAST AGENT; CONTRAST PULSE; CONTRAST-ENHANCED ULTRASONOGRAPHY; FATTY LIVER; HEPATOCELLULAR; LIVER TUMORS; METASTATIC TUMORS; PERIPHERAL ENHANCEMENT;

TUMORS;

SONOVUE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; FATTY LIVER; FEMALE; HEPATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HEMANGIOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; TUMOR DIAGNOSIS;

EID: 70349284490     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2009.28.9.1133     Document Type: Article

References (25)

1. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor- Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14:3476-3483.
2. Fang JG, Zhu J, Li XJ, et al. Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2005; 13:83-88.
3. Chen BH, Cai CY, Liu YQ, Zhang X. Epidemiological approach of prevalence of fatty liver and its risk factors in a general adult population of Jinan. Chin J Nat Med 2007; 9:135-137.
4. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36:1349-1354.
5. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35:1485-1493. (Pubitemid 34966903)
6. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132:1761-1766.
7. Cotrim HP, Paraná R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000; 95:3018-3019.
8. Cuadrado A, Orive A, Garcia-Suarez C, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005; 15:442-446. (Pubitemid 40463617)
9. Konno K, Ishida H, Sato M, et al. Liver tumors in fatty liver: difficulty in ultrasonographic interpretation. Abdom Imaging 2001; 26:487-491. (Pubitemid 32803619)
10. Kim KW, Kim TK, Han JK, et al. Hepatic hemangiomas: spectrum of US appearances on gray-scale, power Doppler, and contrast-enhanced US. Korean J Radiol 2000; 1:191-197.
11. Moody AR, Wilson SR. Atypical hepatic hemangioma: a suggestive sonographic morphology. Radiology 1993; 188:413-417. (Pubitemid 23216261)
12. Liu LP, Dong BW, Yu XL, Zhang DK, Li X, Li H. Analysis of focal spared areas in fatty liver using color Doppler imaging and contrast-enhanced microvessel display sonography. J Ultrasound Med 2008; 27:387-394.
13. Herman P, Costa ML, Machado MA, et al. Management of hepatic hemangiomas: a 14-year experience. J Gastrointest Surg 2005; 9:853-859. (Pubitemid 40883985)
14. Quaia E, Bartolotta TV, Midiri M, Cernic S, Belgrano M, Cova M. Analysis of different contrast enhancement patterns after microbubble-based contrast agent injection in liver hemangiomas with atypical appearance on baseline scan. Abdom Imaging 2006; 31:59-64. (Pubitemid 43081640)
15. Biecker E, Fischer HP, Strunk H, Sauerbruch T. Benign hepatic tumors. Z Gastroenterol 2003; 41:191-200.
16. Bartolotta TV, Midiri M, Galia M, et al. Characterization of benign hepatic tumors arising in fatty liver with SonoVue and pulse inversion US. Abdom Imaging 2007; 32:84-91. (Pubitemid 46742682)
17. Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004; 232:420-430. (Pubitemid 38971282)
18. Lin LW, Yang JJ, Lin XY, et al. Effect of fatty liver background on contrast-enhanced ultrasonographic appearance of focal nodular hyperplasia. Hepatobiliary Pancreat Dis Int 2007; 6:610-615.
19. Liu LP, Dong BW, Yu XL, et al. Value of contrast-enhanced sonography in diagnosing focal nodular hyperplasia of liver. Chin J Ultrasonogr 2006; 15:580-583.
20. Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol 2006; 58:217-228.
21. Xu HX, Liu GJ, Lu MD, et al. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J Clin Ultrasound 2006; 34: 261-272.
22. Leen E, Ceccotti P, Kalogeropoulou C, Angerson WJ, Moug SJ, Horgan PG. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. AJR Am J Roentgenol 2006; 186:1551-1559. (Pubitemid 46112517)
23. Fan ZH, Chen MH, Dai Y, et al. Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology. AJR Am J Roentgenol 2006; 186:1512-1519. (Pubitemid 46112512)
24. Bartolotta TV, Taibbi A, Galia M, et al. Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrastenhanced ultrasound. Eur Radiol 2007; 17:650-661. (Pubitemid 46252343)
25. Wang ZL, Tang J, Weskott HP, et al. Undetermined focal liver lesions on gray-scale ultrasound in patients with fatty liver: characterization with contrast-enhanced ultrasound. J Gastroenterol Hepatol 2008; 23:1511-1519.